BioSpace News Archive

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended March 31, 2021 and provided an update on key milestones.

Cytokinetics, Incorporated reported financial results for the first quarter of 2021. Net loss for the first quarter was $47.1 million, or $0.66 per share, compared to net loss for the first quarter of 2020 of $39.4 million, or $0.66 per share.

Travere Therapeutics, Inc. reported its first quarter 2021 financial results and provided a corporate update.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced financial results for the three months ended March 31, 2021.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported first quarter 2021 financial results and corporate updates.

Ziopharm Oncology, Inc., announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates.

Surgalign Spine Technologies, a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced it has acquired the assets of a fully capable medical device machine shop as a complement to its Spine Innovation Center operations in greater San Diego.

Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session

Amphastar Pharmaceuticals, Inc. reported results for the three months ended March 31, 2021.